<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159926" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dextromethorphan Guaifenesin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kapuria</surname>
            <given-names>Rohan</given-names>
          </name>
          <aff>Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Winston</surname>
            <given-names>Nicole R.</given-names>
          </name>
          <aff>Augusta University Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rohan Kapuria declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nicole Winston declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159926.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Dextromethorphan/guaifenesin is an over-the-counter combination medication used to treat symptoms of productive cough and chest congestion. Dextromethorphan and guaifenesin were invented separately. Dextromethorphan was&#x000a0;invented in 1950 and approved by the FDA in 1958 as a cough suppressant, and guaifenesin was synthesized in 1912 and approved by the FDA in 1952 as an expectorant.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Productive cough caused by common cold</p>
          </list-item>
          <list-item>
            <p>Chest congestion</p>
          </list-item>
          <list-item>
            <p>Productive cough caused by allergies</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute upper respiratory tract infections</p>
          </list-item>
          <list-item>
            <p>Chronic bronchitis&#x000a0;<xref ref-type="bibr" rid="article-159926.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Productive cough for patients with pneumonia&#x000a0;<xref ref-type="bibr" rid="article-159926.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-159926.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Dextromethorphan is an NMDA receptor antagonist&#x000a0;that&#x000a0;nonselectively inhibits the reuptake of serotonin (5-HT) and catecholamines.&#x000a0;Dextromethorphan also agonizes &#x003c3;-1 receptors in the medullary cough center, suppressing the transmission of cough impulses.<xref ref-type="bibr" rid="article-159926.r3">[3]</xref>&#x000a0;</p>
        <p>Guaifenesin is a derivative of xanthine that acts as an expectorant by relaxing bronchial smooth muscle tone. Guaifenesin also irritates the respiratory tract, increasing the volume of fluid in the respiratory tract. Both of these mechanisms contribute to guaifenesin's&#x000a0;reduction of&#x000a0;mucus viscosity.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Dextromethorphan and guaifenesin&#x000a0;are well absorbed in the small intestine.</p>
        <p><bold>Distribution: </bold>Dextromethorphan&#x000a0;has a volume of distribution of 5 to 6.7 L/kg. Dextromethorphan&#x000a0;is lipophilic, has an ionizable amine group, and is structurally similar to alkaloid opioids, but doesn't interact with the &#x003bc; receptor. Guaifenesin has a mean volume of distribution of 116 L.</p>
        <p><bold>Metabolism: </bold>Dextromethorphan is metabolized by the cytochrome P450 enzyme CYP2D6 in the liver into dextrorphan, an active metabolite.&#x000a0;Dextromethorphan also undergoes N-demethylation by CYP3A4. Guaifenesin is also metabolized in the liver and is oxidized to&#x000a0;&#x003b2;-(2-methoxyphenoxy)-lactic acid and unmethylated to hydroxy-guaifenesin. These&#x000a0;2 metabolites of guaifenesin are inactive.</p>
        <p><bold>Excretion:</bold>&#x000a0;Dextrorphan,&#x000a0;&#x003b2;-(2-methoxyphenoxy)-lactic acid, and hydroxy-guaifenesin are excreted by the kidneys in urine.&#x000a0;</p>
      </sec>
      <sec id="article-159926.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Forms</bold>
</p>
        <p>Dextromethorphan and guaifenesin are administered orally&#x000a0;via&#x000a0;various formulations, including&#x000a0;capsules, granules, syrup, liquid drops, and tablets (timed or extended-release).</p>
        <p>
<bold>Available Strengths</bold>
</p>
        <p><bold>Capsule:&#x000a0;</bold>10 to 200 mg</p>
        <p><bold>Granules:&#x000a0;</bold>(5 to 100 mg)/packet</p>
        <p>
<bold>Liquid</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>(5 to 100 mg)/5 mL</p>
          </list-item>
          <list-item>
            <p>(10 to 100 mg)/5 mL</p>
          </list-item>
          <list-item>
            <p>(10 to 187 mg)/5 mL</p>
          </list-item>
          <list-item>
            <p>(10 to 200 mg)/5 mL</p>
          </list-item>
          <list-item>
            <p>(15 to 200 mg)/5 mL</p>
          </list-item>
          <list-item>
            <p>(20 to 200 mg)/5 mL</p>
          </list-item>
          <list-item>
            <p>(15 to 150 mg)/7.5 mL</p>
          </list-item>
          <list-item>
            <p>(10 to 100 mg)/10 mL</p>
          </list-item>
        </list>
        <p>
<bold>Tablet</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>15 to 400 mg</p>
          </list-item>
          <list-item>
            <p>20 to 400 mg</p>
          </list-item>
        </list>
        <p>
<bold>Tablet, Extended-Release</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>30 to 600 mg</p>
          </list-item>
          <list-item>
            <p>60 to 1200 mg</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The most common OTC syrup formulation is administered in 10 mL&#x000a0;(dextromethorphan 20 mg, guaifenesin 200 mg) increments every 4 hours, which&#x000a0;should not exceed&#x000a0;60 mL daily.</p>
        <p>Tablet form dosing is 1 to 2 tablets every 12 hours with a maximum daily&#x000a0;ingestion of 4 tablets.&#x000a0;There is also a "maximum strength" tablet, administered as a single&#x000a0;tablet every 12 hours and a maximum of 2 tablets every 24 hours.</p>
        <p>The granule form of this medication is dosed&#x000a0;as 2 to 4 packets every 4 hours with a maximum of 6 doses every 24 hours.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> No dose adjustment is&#x000a0;advised in the manufacturer label for patients with hepatic impairment.&#x000a0;</p>
        <p><bold>Renal impairment:</bold> No dose adjustment is&#x000a0;advised in the manufacturer label for patients with&#x000a0;renal impairment.</p>
        <p><bold>Pregnancy considerations: </bold>These medications should be considered individually based on their pharmacokinetic and pharmacodynamic properties. Guaifenesin at normal OTC doses is acceptable. In contrast, dextromethorphan is metabolized by liver enzymes CYP2D6 and CYP3A. The&#x000a0;activity of these enzymes&#x000a0;is elevated&#x000a0;during pregnancy.<xref ref-type="bibr" rid="article-159926.r4">[4]</xref></p>
        <p><bold><bold>Breastfeeding considerations:</bold></bold>&#x000a0;Dextromethorphan and dextrorphan are&#x000a0;minimally present&#x000a0;in breast milk and do not affect the infant.<xref ref-type="bibr" rid="article-159926.r5">[5]</xref>&#x000a0;No studies have been conducted regarding the excretion of guaifenesin in breast milk, nor have studies been conducted on the effects of breastfeeding on infants.<xref ref-type="bibr" rid="article-159926.r6">[6]</xref>&#x000a0;</p>
        <p><bold>Pediatric patients: </bold>There is limited data on the safety and efficacy of dextromethorphan and guaifenesin in infants and children. The FDA recommends against&#x000a0;using these medications for pediatric patients.&#x000a0;</p>
        <p><bold>Older&#x000a0;patients:&#x000a0;</bold>No specific dose adjustment is needed for older adults.&#x000a0;</p>
        <p>Dextromethorphan and guaifenesin are typically administered to adults in an&#x000a0;extended-release suspension, which must be shaken to be&#x000a0;absorbed correctly.<xref ref-type="bibr" rid="article-159926.r7">[7]</xref>&#x000a0;According to the American Academy of Pediatrics,&#x000a0;dextromethorphan and guaifenesin&#x000a0;shouldn't be administered to children younger than 4. However, some studies state that dextromethorphan and guaifenesin can be administered to children 2 years old or older in liquid form, but caregivers must accurately measure the liquid amount.<xref ref-type="bibr" rid="article-159926.r8">[8]</xref></p>
      </sec>
      <sec id="article-159926.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Dextromethorphan and guaifenesin have multiple adverse&#x000a0;reactions&#x000a0;that primarily&#x000a0;affect the cardiovascular, neurologic, psychiatric, musculoskeletal, renal, and gastrointestinal systems.&#x000a0;</p>
        <p>Renal adverse effects include acute renal failure and nephrolithiasis, which are caused by the&#x000a0;guaifenesin&#x000a0;component of this combination drug.&#x000a0;Less common&#x000a0;adverse reactions&#x000a0;include severe flank pain, hematuria, and oliguria.<xref ref-type="bibr" rid="article-159926.r9">[9]</xref><xref ref-type="bibr" rid="article-159926.r10">[10]</xref>&#x000a0;</p>
        <p>Psychiatric adverse effects include a type of psychosis that presents similarly to phencyclidine (PCP) intoxication, which is characterized by paranoid feelings, hallucinations, and delusions.<xref ref-type="bibr" rid="article-159926.r11">[11]</xref>&#x000a0;This is partially&#x000a0;due to dextrorphan, which&#x000a0;noncompetitively antagonizes NMDA receptors. Similarly to PCP and ketamine, dextromethorphan and guaifenesin also cause insomnia; these 4 drugs have similar mechanisms of action, so they cause similar&#x000a0;psychosis symptoms. This&#x000a0;similarity&#x000a0;means dextromethorphan and guaifenesin also pose a high risk for abuse,&#x000a0;especially since these medications are available over the counter.<xref ref-type="bibr" rid="article-159926.r12">[12]</xref>&#x000a0;</p>
        <p>Dextromethorphan and guaifenesin&#x000a0;may cause rhabdomyolysis and subsequent electrolyte abnormalities, including&#x000a0;hyperphosphatemia, hyperkalemia, hypomagnesemia, and hypocalcemia.<xref ref-type="bibr" rid="article-159926.r13">[13]</xref></p>
        <p>Gastrointestinal adverse effects include&#x000a0;nausea, vomiting, abdominal pain, and diarrhea. Other common side effects include dizziness and drowsiness.</p>
        <p>Dextromethorphan and guaifenesin can affect the cardiovascular system, causing tachycardia and hypertension. These medications may also cause a severe type I hypersensitivity reaction caused by an exaggerated IgE response, which would present with rash, dyspnea, dizziness, and swelling of any part of the oral cavity or face.&#x000a0;Dextromethorphan and guaifenesin should generally be avoided in pediatric patients, as there is a lack of evidence for&#x000a0;their use&#x000a0;in children.<xref ref-type="bibr" rid="article-159926.r14">[14]</xref>&#x000a0;Instead, children&#x000a0;should be given honey, saline nasal spray, or&#x000a0;more fluids to suppress cough; these treatments have&#x000a0;minimal or absent risk&#x000a0;for adverse effects.&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dextromethorphan and guaifenesin may interact with medications that cause respiratory depression, such as benzodiazepines, opioids, and alcohol.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dextromethorphan and guaifenesin may interact with medications that affect heart rhythm, such as amiodarone, procainamide, and quinidine.</p>
          </list-item>
          <list-item>
            <p>Dextromethorphan and guaifenesin may interact with medications that affect serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),&#x000a0;and monoamine oxidase inhibitors (MAOIs).</p>
          </list-item>
          <list-item>
            <p>Dextromethorphan may interact with agents that affect blood sugar levels, such as insulin, sulfonylureas, or metformin.</p>
          </list-item>
          <list-item>
            <p>Dextromethorphan and guaifenesin may interact with medications that affect CYP enzyme metabolism, such as rolapitant.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-159926.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications for dextromethorphan and guaifenesin&#x000a0;therapy include&#x000a0;concomitant monoamine oxidase inhibitor (MAOI) administration. This combination drug is also contraindicated for patients with phenylketonuria, severe liver or kidney disease, patients younger than 4 years old, patients with known hypersensitivity reactions to dextromethorphan or guaifenesin, and patients with a&#x000a0;history of kidney stones.&#x000a0;</p>
        <p>MAOIs are used&#x000a0;to treat refractory depression&#x000a0;by inhibiting MAO-A and MAO-B. MAO-A metabolizes monoamine neurotransmitters such as dopamine, serotonin, and dopamine. Thus, MAOIs can increase serotonin levels in the brain. Dextromethorphan and guaifenesin also increase serotonin levels.&#x000a0;Administering these medications simultaneously increases&#x000a0;the&#x000a0;risk&#x000a0;for serotonin syndrome, a life-threatening drug reaction characterized by neuromuscular hyperactivity, autonomic hyperstimulation, and agitation.<xref ref-type="bibr" rid="article-159926.r15">[15]</xref>&#x000a0;To avoid serotonin syndrome, dextromethorphan and guaifenesin should not be taken within 14 days of MAOI use or any other drug that increases serotonergic neurotransmission.</p>
        <p>Dextromethorphan and guaifenesin are contraindicated for patients with phenylketonuria. These patients have&#x000a0;deficient levels of phenylalanine hydroxylase, an enzyme that converts phenylalanine to tyrosine. Some formulations of dextromethorphan and guaifenesin contain phenylalanine and thus can cause neurological conditions,&#x000a0;including seizures, intellectual disability, and tremors.<xref ref-type="bibr" rid="article-159926.r16">[16]</xref></p>
        <p>Dextromethorphan and guaifenesin can cause neonatal gasping syndrome due to&#x000a0;trace amounts of benzyl alcohol found in some formulations. Benzyl alcohol causes neonatal gasping syndrome in premature infants and neonates by inducing respiratory distress and central nervous system (CNS) depression.&#x000a0;Benzyl alcohol accumulation also causes&#x000a0;elevated lactate and&#x000a0;reduced bicarbonate levels,&#x000a0;resulting in anion gap metabolic acidosis.<xref ref-type="bibr" rid="article-159926.r17">[17]</xref></p>
        <p>Dextromethorphan and guaifenesin are contraindicated for patients with a history of kidney stones, as guaifenesin increases the risk of kidney stones, albeit minimally.<xref ref-type="bibr" rid="article-159926.r10">[10]</xref>&#x000a0;The mechanism of this adverse effect involves supersaturation&#x000a0;and crystallization of urine.&#x000a0;Kidney stone occurrence after administration of this drug combination has&#x000a0;only been described in case reports, but this is enough reason to avoid the use of this medication&#x000a0;for patients already at high risk for nephrolithiasis.</p>
        <p>Dextromethorphan and guaifenesin are contraindicated&#x000a0;for&#x000a0;patients&#x000a0;younger than 4 years&#x000a0;old,&#x000a0;as this drug combination may cause death in this age group.&#x000a0;Overdose is possible, and&#x000a0;children in this age group&#x000a0;must not be allowed access to these medications. The Centers for Disease Control and Prevention (CDC) released a policy statement stating that cough suppressants such as dextromethorphan and guaifenesin have no proven efficacy in treating acute cough in this demographic and should be avoided due to the chance of adverse effects.<xref ref-type="bibr" rid="article-159926.r18">[18]</xref></p>
      </sec>
      <sec id="article-159926.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Dextromethorphan and guaifenesin use should be monitored carefully in patients with "poor metabolizer" CYP2D6 enzyme levels and patients who are sedated. This combination medication&#x000a0;has a&#x000a0;large&#x000a0;median toxic dose (TD50) to median effective dose (ED50) ratio (or therapeutic index) in these patients.&#x000a0;Dextromethorphan and guaifenesin are&#x000a0;typically well tolerated if the&#x000a0;contraindications listed above are observed.</p>
        <p>Close monitoring is necessary if dextromethorphan and guaifenesin are taken with oral rolapitant. This drug increases the exposure of substrates metabolized by CYP2D6, such as dextromethorphan and guaifenesin. One study found that a single&#x000a0;tablet of rolapitant increased the overall dextromethorphan exposure by 3 times compared to the original dose. Patients who take this drug combination and have "poor metabolizing" CYP2D6 activity must be monitored,&#x000a0;as genetics or concomitant drug usage affects this enzyme.<xref ref-type="bibr" rid="article-159926.r19">[19]</xref>&#x000a0;Guaifenesin&#x000a0;can falsely elevate vanillylmandelic acid levels.<xref ref-type="bibr" rid="article-159926.r20">[20]</xref></p>
      </sec>
      <sec id="article-159926.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Dextromethorphan and guaifenesin&#x000a0;have abuse potential. Persons who abuse it or take an increased amount are at risk for overdose.<xref ref-type="bibr" rid="article-159926.r3">[3]</xref></p>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Dextromethorphan and guaifenesin toxicity occurs in different stages, which users refer to as "plateaus." The first "plateau" occurs at 1.5 mg/kg, a dosage causing mild stimulation. The second "plateau" occurs at 2.5 to 7.5 mg/kg; users may experience mild to moderate euphoria and hallucinations. At the third "plateau" of 7.5 to 15 mg/kg, the patient may experience dissociation that some&#x000a0;have described as an "out-of-body" state. Finally, at the fourth "plateau," patients experience complete dissociation and&#x000a0;become&#x000a0;nonresponsive.&#x000a0;</p>
        <p>Other signs and symptoms associated with overdose of dextromethorphan and guaifenesin include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dyspnea</p>
          </list-item>
          <list-item>
            <p>Blurred vision</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Hyperthermia</p>
          </list-item>
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Altered mental status</p>
          </list-item>
        </list>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no specific antidote for an overdose of this combination medication, and management is symptomatic. Activated charcoal may absorb dextromethorphan and guaifenesin in the small intestine and stomach, preventing their enterohepatic and vascular circulation and absorption and reducing toxic effects.</p>
        <p>
<bold>Recommendations</bold>
</p>
        <p>If the patient has difficulty breathing, supplemental oxygen and assisted ventilation may be given.&#x000a0;Management is typically supportive&#x000a0;while monitoring vital signs and electrolyte&#x000a0;levels.&#x000a0;Naloxone&#x000a0;can reverse coma and respiratory depression in patients who have overdosed but should not be used as a substitute for supportive care.<xref ref-type="bibr" rid="article-159926.r21">[21]</xref></p>
      </sec>
      <sec id="article-159926.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients&#x000a0;with a productive cough&#x000a0;as a symptom of the common cold, allergies, or chest congestion can use dextromethorphan and guaifenesin to relieve their symptoms acutely. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals&#x000a0;must know this combination's pharmacodynamic properties, adverse effects, and monitoring goals. Because dextromethorphan and guaifenesin&#x000a0;are commonly purchased&#x000a0;over the counter, practitioners and pharmacists should also educate patients on recommended dosages&#x000a0;based on mucus production and cough severity.&#x000a0;</p>
        <p>Ethical considerations include ensuring patient autonomy&#x000a0;and education on the recommended doses to prevent overdose. Interprofessional collaboration is essential&#x000a0;to ensure proper dosing for patients taking this&#x000a0;medication combination. Prevention or management of overdose occurs&#x000a0;when the paramedics reach the scene of an overdose, the triage nurse suspects an overdose upon patient arrival, or the physician informs the patient of proper dosing of this medication. This coordination between healthcare professionals enhances patient education to prevent overdose,&#x000a0;treats symptoms and ensures patient safety.</p>
      </sec>
      <sec id="article-159926.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159926&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159926">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159926/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159926">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159926.s10">
        <title>References</title>
        <ref id="article-159926.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Donohue</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Spangenthal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review.</article-title>
            <source>Chronic Obstr Pulm Dis</source>
            <year>2019</year>
            <month>Oct</month>
            <day>23</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>341</fpage>
            <page-range>341-9</page-range>
            <pub-id pub-id-type="pmid">31647856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albrecht</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Dicpinigaitis</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Guenin</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections.</article-title>
            <source>Multidiscip Respir Med</source>
            <year>2017</year>
            <volume>12</volume>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">29238574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Journey</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <chapter-title>Dextromethorphan Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">30860737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tracy</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Venkataramanan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Glover</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Caritis</surname>
                <given-names>SN</given-names>
              </name>
              <collab>National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units</collab>
            </person-group>
            <article-title>Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>192</volume>
            <issue>2</issue>
            <fpage>633</fpage>
            <page-range>633-9</page-range>
            <pub-id pub-id-type="pmid">15696014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <chapter-title>Dextromethorphan</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <chapter-title>Guaifenesin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malesker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Callahan-Lyon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ireland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>RS</given-names>
              </name>
              <collab>CHEST Expert Cough Panel</collab>
            </person-group>
            <article-title>Pharmacologic and Nonpharmacologic Treatment for Acute Cough Associated With the Common Cold: CHEST Expert Panel Report.</article-title>
            <source>Chest</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>152</volume>
            <issue>5</issue>
            <fpage>1021</fpage>
            <page-range>1021-1037</page-range>
            <pub-id pub-id-type="pmid">28837801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karabacak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Margetis</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Natural language processing reveals research trends and topics in The Spine Journal over two decades: a topic modeling study.</article-title>
            <source>Spine J</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>397</fpage>
            <page-range>397-405</page-range>
            <pub-id pub-id-type="pmid">37797843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Small</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sandefur</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Acute renal failure after ingestion of guaifenesin and dextromethorphan.</article-title>
            <source>J Emerg Med</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-9</page-range>
            <pub-id pub-id-type="pmid">24630853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Perlmutter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zweber</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Resch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bilateral nephrolithiasis following ingestion of guaifenesin and dextromethorphan.</article-title>
            <source>Urol Case Rep</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>50</volume>
            <fpage>102481</fpage>
            <pub-id pub-id-type="pmid">37455782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bolis</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Fargason</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Birur</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Dextromethorphan in Cough Syrup: The Poor Man's Psychosis.</article-title>
            <source>Psychopharmacol Bull</source>
            <year>2017</year>
            <month>Sep</month>
            <day>15</day>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>59</fpage>
            <page-range>59-63</page-range>
            <pub-id pub-id-type="pmid">28936010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vaughn</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Identifying and treating patients with synthetic psychoactive drug intoxication.</article-title>
            <source>JAAPA</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">30048361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Stanley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chippa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Quintanilla Rodriguez</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Adigun</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Rhabdomyolysis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">28846335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Banner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bond</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Safety Profile of Cough and Cold Medication Use in Pediatrics.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>139</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28562262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francescangeli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karamchandani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonavia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>May</month>
            <day>09</day>
            <volume>20</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31075831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Spronsen</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Blau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burlina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Phenylketonuria.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2021</year>
            <month>May</month>
            <day>20</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <pub-id pub-id-type="pmid">34017006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershanik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boecler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ensley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McCloskey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The gasping syndrome and benzyl alcohol poisoning.</article-title>
            <source>N Engl J Med</source>
            <year>1982</year>
            <month>Nov</month>
            <day>25</day>
            <volume>307</volume>
            <issue>22</issue>
            <fpage>1384</fpage>
            <page-range>1384-8</page-range>
            <pub-id pub-id-type="pmid">7133084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hendeles</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Why Is Oral Phenylephrine on the Market After Compelling Evidence of Its Ineffectiveness as a Decongestant?</article-title>
            <source>Ann Pharmacother</source>
            <year>2022</year>
            <month>Mar</month>
            <day>25</day>
            <fpage>10600280221081526</fpage>
            <pub-id pub-id-type="pmid">35337187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kansra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.</article-title>
            <source>Support Care Cancer</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>819</fpage>
            <page-range>819-827</page-range>
            <pub-id pub-id-type="pmid">30084103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kremers</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoobler</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Studies of urinary VMA as a screening procedure for phaeochromocytoma.</article-title>
            <source>Cardiologia (Basel)</source>
            <year>1967</year>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>98</fpage>
            <page-range>98-108</page-range>
            <pub-id pub-id-type="pmid">5595278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159926.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shinde</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Khuraijam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puthoor</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Two Cases of Dextromethorphan Overdose Reversed by Naloxone.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>e34501</fpage>
            <pub-id pub-id-type="pmid">36874326</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
